The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 09, 2021

Filed:

Jun. 09, 2020
Applicant:

The Regents of the University of Michigan, Ann Arbor, MI (US);

Inventors:

Joseph Holoshitz, Ann Arbor, MI (US);

Andrew White, Ann Arbor, MI (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/454 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); A61P 19/00 (2006.01); A61K 45/06 (2006.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
C07D 401/14 (2013.01); A61K 31/454 (2013.01); A61K 45/06 (2013.01); A61P 19/00 (2018.01); A61P 37/06 (2018.01); C07D 405/14 (2013.01);
Abstract

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a triazole-methyl-piperidinyl-pyrolyl-propenone structure which function as modulators of shared epitope (SE)—calreticulin (CRT) binding and/or interaction, and their use as therapeutics for the treatment of immunoregulatory abnormalities (e.g., autoimmune diseases, inflammatory diseases (e.g., chronic inflammatory disease), and bone erosive diseases) by selectively inhibiting SE-CRT interactions and/or signal transduction pathways commonly overactive or dysregulated in arthritic and/or other diseases or conditions.


Find Patent Forward Citations

Loading…